ERBB2 and neoplasm: Besides HR-positive disease, CDK4/6-Is are currently investigating in HER2-overexpressing and triple-negative BCs.47 Furthermore, the recently reported immunomodulatory activity of the CDK4/6-Is in preclinical tumor models66 paved the way to test these agents in combination with immune checkpoint inhibitors.